Press Releases Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Market Closed - Nasdaq Other stock markets 21:00:00 01/05/2024 BST			5-day change	1st Jan Change
63.71 ^USD	+5.22%		+4.65%	+1.45%

04-25	Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing	MT
04-22	Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference	04-02	GL
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants	03-04	GL
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	02-27	GL
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024	02-15	GL
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	02-02	AQ
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	02-02	GL
Vaxcyte to Present at the Guggenheim Healthcare Talks \| 6th Annual Biotechnology Conference	02-01	GL
Vaxcyte Announces Pricing of $750 Million Public Offering	01-31	GL
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants	01-30	GL
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older	01-29	GL
Vaxcyte Appoints Whitney Jones as Chief People Officer	01-16	GL
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise	01-04	GL
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate	12-04	GL
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate	12-04	AQ
Vaxcyte Appoints Jacks Lee to Board of Directors	11-28	GL
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates	11-27	GL
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates	11-27	AQ
Chronic Periodontitis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	11-14	AQ
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults	11-09	GL
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update	11-06	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Press Releases

Filters